The impact of blood utilization guidelines on product usage

Authors: Catherine Montemore, Yuliya Dobrydneva, Marcia Firmani*

Catherine Montemore:
Blood Bank Department at Frederick Memorial Hospital
George Washington University – School of Medicine and Health Sciences

Yuliya Dobrydneva and Marcia Firmani
The George Washington University
School of Medicine and Health Sciences
Department of Biomedical Laboratory Sciences
44983 Knoll Square
Ashburn, VA 20147

*Corresponding Author:
Marcia Firmani, PhD, MSPH, MT(ASCP)MB
e-mail: firmanim@gwu.edu
phone: (202) 994-8338

No Conflict of Interest
Word Count = 3934
Abstract

In 2012, Frederick Memorial Hospital (FMH) revitalized their blood utilization guidelines to follow a more restrictive approach to blood product transfusions. With help from the American Red Cross and the American Association of Blood Banks, the blood utilization committee at FMH established a set of blood transfusion guidelines, and educated and enforced all ordering physicians to follow the new set of guidelines. Since the guidelines were established, the amount of red blood cell transfusions decreased by 34%, plasma transfusions decreased by 55%, and platelet transfusions decreased by 34%. These decreases have reduced the number of patients exposed to the possibility of transfusion-adverse reactions and related side effects. Reported transfusion reactions since 2012 decreased by 51%. By using a more restrictive set of guidelines the blood utilization committee was able to achieve their goals, which included 1) reducing the high cost associated with blood transfusion, 2) improving patient care, and 3) educating physicians regarding current transfusion protocols and techniques, while concurrently decreasing transfusion-related adverse events. The successful process used at FMH may be useful for other similar health care settings.
INTRODUCTION:

The Joint Commission (JC) requires the medical institutions it governs to conform to a list of regulations, including the formation of blood utilization guidelines. By establishing guidelines for blood utilization, hospitals and other medical facilities are able to comply with JC’s regulation for continual improvement of health care for all patients.¹ At JC’s overuse summit in 2012, it was noted that red blood cell transfusions were the most commonly performed and the most overused procedure in U.S. hospitals.¹ Blood utilization guidelines can help hospitals reduce the number of blood transfusions by educating physicians on new standards that indicate the symptoms and laboratory results that deem it necessary for a patient to receive a blood product transfusion.

Frederick Memorial Hospital (FMH), an affiliate of Frederick Regional Health System (FRHS), is a 240-bed local hospital in Frederick, Maryland. It is a not-for-profit, short-term, acute care facility. FRHS consists of multiple off-site locations that offer a variety of services, including outpatient laboratory and radiology services, home health services, hospice care, oncology care, wellness and fitness support, corporation health services, and a large network of physician offices that offer multiple medical specialties.² FMH is not a trauma center, but it has been utilized for trauma situations where a patient cannot make the trip to a trauma center without being stabilized.

Prior to 2012, the transfusion guidelines at FMH consisted of five rules: (1) a normovolemic patient with symptomatic anemia regardless of their hemoglobin value; (2) acute loss of ≥ 15% of estimated blood volume; (3) acute blood loss with evidence of inadequate oxygen delivery; (4) preoperative hemoglobin ≤ 8 g/dL and operative procedure associated with major blood loss; and (5) hemoglobin ≤ 8 g/dL in a patient on a chronic transfusion regimen.
These guidelines were internal suggestions that physicians could use to determine if a transfusion of any blood product was needed for their patients. Unfortunately, these guidelines were not enforced and, therefore, not always followed by all of the ordering physicians.

In 2012, a Premiere report identified that FMH transfused more blood products than their peers. The blood bank supervisor, Lori Park-Dovell, researched the AABB recommendations, attended American Red Cross lectures, and called local hospitals to determine recommendations for the FMH physician staff. Subsequently, a blood utilization committee was formed and they decided to revise their blood utilization guidelines with goals to reduce the high cost of blood transfusions, improve patient care, and educate physicians on newer ideas and/or techniques. The blood utilization committee consisted of the Blood Bank Supervisor, Medical Director of the Laboratory, Pathologist Associates, Clinical Specialist Nurses, and several hospital affiliated physicians. The committee communicated with the physicians and used their input to determine the new guidelines. Specific care was taken toward both cardiac and oncology patients since these patient populations are at risk for needing blood products to treat their ailments. The new guidelines were introduced to physicians through education, and facilitated with assistance from the LIS software, Meditech, and the blood bank technologists. Physicians were required to fill out transfusion order forms that listed the new guidelines as a way to encourage them to document the reason for the transfusion order. They were required to write down laboratory results, such as hemoglobin and/or hematocrit or platelets counts, to support their desire to transfuse their patients. Progress reports were evaluated monthly and the blood utilization committee addressed any concerns with the ordering physicians or their direct supervisor.

**MATERIALS AND METHODS:**
New FMH Guidelines 2012

The new guidelines set up by the FMH blood utilization committee took time and research to determine the criteria for blood product transfusions. All blood product transfusion thresholds were derived from data and research provided by the experts at the American Red Cross (ARC) and AABB. Based on published studies, it was suggested that a restrictive transfusion trigger should be utilized and each patient needed to be assessed individually and carefully. For example, a hemoglobin value should be used when considering a patient for a transfusion. Although there is limited data available, the lowest threshold tested was a hemoglobin of 7 g/dL. However, patients may still not require a transfusion even if the trigger level of hemoglobin is reached. In addition, physicians need to consider a physical examination and carefully evaluate the patient’s history. If the patient is clinically stable, the physician can refrain from transfusing blood products. For oncology patients, transfusions can be based on symptoms as opposed to only looking at the patient test results. Data suggests that GI bleed patients should be included in the restrictive transfusion plan. Research has proven that there is an increase in the 45-day survival rate with restrictive therapy. However, transfusion guidelines should not replace clinical judgement. Table 1 shows a comparison of the 2008 and 2012 triggers for blood product transfusions.

Red Blood Cell Transfusion Recommendations

Red blood cell transfusion guidelines at FMH are based on the hemoglobin, hematocrit, and patient symptoms. Any patient who has rapid blood loss with an estimated blood loss of greater than 20% and are not responding to volume resuscitation or with ongoing blood loss do not require specific hemoglobin or hematocrit values to receive red blood cell transfusions. The
physician can document the specific reason justifying a red blood cell transfusion for a patient. This case would then be reviewed by the blood utilization committee at their quarterly meeting.

Several trials were studied and reviewed by the ARC and AABB to evaluate the risk bias, allocation concealment, blinding, and incomplete outcome data. The relative risk was also evaluated in each trial to compare the control group with the intervention group. A summary of several clinical trials prepared by the ARC was used to aid in the selection of FMH’s blood utilization guidelines. For example, the TRICC trial tested 838 ill patients with euvolemia at both hemoglobin levels of 9 g/dL and 7 g/dL. Patients were randomly assigned to the restrictive transfusion group and the conservative group. Both groups had similar mortality rates after the 30-day trial. Acute Physiology and Chronic Health Evaluation II scores were calculated for each group of patients. The rates were significantly lower in the restrictive transfusion group at 8.7% compared to 16.1% in the conservative transfusion group.

The Focus Trial researched high-risk patients after they experienced hip surgery. This trial used hemoglobin values of 10 g/dL and 8 g/dL to differentiate between their restrictive and liberal group of patients. Restrictive patients on average received no red blood cell transfusions, while the liberal patients on average received two units of red blood cells. Primary outcome rates of death or unable to walk across the room without assistance were as follows: the restrictive group was 34.7% and the liberal group was 35.2%.

The TRIPICU Trial focused on pediatric patients in the intensive care unit and hemoglobin thresholds of 9.5 g/dL and 7 g/dL were used to determine which group patients were randomly placed in with regard to the restrictive or conservative group. Patients in the restrictive group were able to maintain their lower hemoglobin value over the liberal group.

Overall, the studies showed that patients with lower hemoglobin values are able to remain stable without needing a red blood cell transfusion. FMH’s guidelines align with those suggested
in the AABB publication. The AABB Technical Manual clearly states that any patient with a hemoglobin level less than 6 g/dL almost always requires a red blood cell transfusion and patients with a hemoglobin level greater than 10 g/dL rarely require a red blood cell transfusion.\textsuperscript{7}

**Platelet Transfusion Recommendations**

Platelet transfusion guidelines are based on the patient’s symptoms and platelet values. Any patient who has been diagnosed with a platelet dysfunction disorder documented by a test result or medication is recommended to receive a platelet transfusion without having a specific platelet count. In 1994, a paper published in the journal *Transfusion* provided transfusion guidelines for several blood products. This guideline, although not an official recommendation of the AABB, reviewed and suggested transfusion guidelines for several blood products. It recommended that patients should receive a platelet transfusion to “prevent or control bleeding associated with deficiencies in platelet number or function”.\textsuperscript{5} Patients who are not bleeding, cannot produce platelets, and have a platelet count of less than 10,000/uL were recommended to receive a platelet transfusion.\textsuperscript{5} A patient with a platelet count less than 50/uL and is having invasive or non-invasive surgery is suggested to receive a platelet transfusion.\textsuperscript{5} The AABB Technical Manual discusses the need to not only take into consideration the platelet count, but also several other factors before deciding if a transfusion is necessary. Patients may need to have platelet function and coagulation deficiency testing, and the patient’s history should always be taken into consideration.\textsuperscript{4} In some actively bleeding patients or those patients having surgery that may involve significant blood loss can benefit from thromboelastography testing. Current thresholds provided by AABB can be found in Table 2. These guidelines are similar to the those chosen by the blood utilization committee at FMH described at the beginning of this section.
Plasma Transfusion Recommendations

Plasma transfusion guidelines are based on both a patient’s symptoms and/or their INR or APTT results. Patients who are in need of an emergency reversal of warfarin treatment or are diagnosed with thrombotic thrombocytopenic purpura (TTP), or hemolytic uremic syndrome (HUS) are recommended to receive a plasma transfusion without having a specific laboratory value. Patients who have an INR result greater than 1.6 or an APTT greater than 40 are recommended to receive a plasma transfusion, if they are also actively bleeding or undergoing an invasive procedure.

There are very limited guideline recommendations from the AABB Technical Manual, since there is sparse research data available. Massive transfusion scenarios and patients who require warfarin reversal are the main critical reasons for a patient to receive a plasma transfusion. Since the research data is very limited, as previously stated, there currently are no guidelines for transfusions in patients who are not in a critical situation. This field needs to be further researched to determine if there are other scenarios that would suggest the need for a plasma transfusion.

Cryoprecipitate Transfusion Recommendations

Cryoprecipitate transfusion guidelines are based on both a patient’s symptoms and their fibrinogen value. Any patient with a fibrinogen less than 100 mg/dL is recommended to receive a cryoprecipitate transfusion. When Desmopressin (DDAVP), Human P, or any other comparable factor concentrate is not available, a patient with Von Willebrand’s disease is recommended to receive a cryoprecipitate transfusion. A patient in renal failure with an abnormal clotting time
and is either actively bleeding, had surgery, or had an invasive procedure within the last 24 hours is recommended to receive a cryoprecipitate transfusion.

The AABB Technical Manual states that the fibrinogen level is extremely important to determine if a cryoprecipitate transfusion is needed. It is recommended that a patient maintains a fibrinogen level of at least 100 mg/dL. If a patient is consuming fibrinogen due to being in DIC or losing fibrinogen due to a massive hemorrhage, cryoprecipitate product may be required to increase the fibrinogen in the patient. The most important part of transfusing cryoprecipitate is knowing how many units are required to maintain a specific fibrinogen level. Cryoprecipitate is a low volume blood product, and a patient may require several units to achieve the desired fibrinogen level.

RESULTS:

**Red blood cells:** Overall, the number of blood products transfused at FMH has been in decline since the introduction and reinforcement of the 2012 blood utilization guidelines. Yearly totals of red blood cells transfused are shown in Figure 1.

In 2010, 5,401 irradiated and non-irradiated red blood cell products were transfused. In 2013, there was a decrease of red blood cell products transfused (4,329 vs 5,401). In the year 2017, there were only 3,297 red blood cell products transfused. This is a 39% decrease since 2010 and a 24% decreased since 2013.

**Plasma:** This constant declining trend continues with the plasma transfusions recorded at FMH, (see Table 2). In 2012, there were 1,041 units of plasma transfused and in 2017 there
were 465 units of plasma transfused. Therefore, there is a decrease of 55% of plasma units transfused over the course of five years. By far, this is the best improvement score across all of the blood products transfused at FMH.

**Cryoprecipitate:** Cryoprecipitate has always been the lowest volume of products transfused. As seen in Figure 3, the number of cryoprecipitate units has fluctuated through the years due to the types of patient admitted to FMH requiring a cryoprecipitate transfusion. FMH is not a trauma center and therefore does not receive patient who may require a massive transfusion. In 2010, 58 units of cryoprecipitate were transfused and in 2012 only 18 units were transfused. In 2013, the number of units of cryoprecipitate transfused increased to 63 units. In 2017, only 7 units of cryoprecipitate were transfused.

**Platelets:** Both irradiated and non-irradiated platelets are a constantly transfused product at FMH due to the MD Anderson Cancer Center association with the hospital. The number of platelet products transfused is shown in Figure 4. As with cryoprecipitate products, the number of platelets transfused has fluctuated since 2010. Between 2010 and 2012 there was a 17% decrease in the number of platelet products transfused. However, in 2014 there was a slight increase in the total number of platelet units transfused. This increased could be due to an increase in the oncology population being treated at our cancer treatment center requiring platelet transfusions. From 2014 through 2017 there has been a 34% decrease in the number transfused.

**Transfusion reactions:** One of the biggest risks for a patient when receiving any kind of blood product is the exposure to possible reactions to the transfusion itself, including illness,
allergies, and even death. Over the last seven years, the number of transfusion reactions has drastically decreased, possibly due to the decrease in the number of products transfused. Values for the number of transfusion reactions are shown in Figure 5. Since 2012, the number of transfusion reactions has decreased by 51%. This is a significant improvement in the number of reactions. To illustrate the breakdown by categories of infusion reactions, in 2017, three of the seventeen recorded transfusion reactions were determined to be an allergic or anaphylactic reaction to the product. Ten of the recorded transfusion reactions were due to febrile, non-hemolytic reaction to the product, and four were determined to be another reason other than those typically reported. The four outliers may be incorrectly called transfusion reactions.

**DISCUSSION:**

As seen in the studies provided by the ARC, patients tend to have better outcomes when treated with restrictive blood utilization guidelines. This is due to the fact that fewer patients are being exposed to potential side effects associated with blood product transfusions. Instead of transfusions, patients are being treated with medication or naturally by allowing the patient’s blood production system to improve their status.

Based on these findings, FMH decided to adjust their blood utilization guidelines in 2012 with the goals of reducing the cost of blood transfusions, improving patient care, and educating physicians to use the new guidelines appropriately as part of their clinical tools. Since 2012, the blood bank at FMH has been able to reduce the amount of inventoried red blood cells kept at the hospital. This outcome was observed in two similar studies that showed a reduction in red blood cell utilization. For example, a study at Stanford Hospital and Clinics used real-time clinical decision support to assist physicians when placing orders for blood product transfusions. At the
time the process was initiated in 2009 until 2012 the percentage of patients transfused with red blood cells for patients with a hemoglobin value greater than 8 g/dL decreased from 66% to less than 30%. Overall blood components also decreased during this timeframe resulting in a cost saving of greater than 1.6 million dollars. Another study at the John Hopkins Hospital System established a patient blood management program that initiated a campaign for promoting single-unit red blood cell transfusion. Whenever a patient’s hemoglobin was greater than 7 g/dL, a “pop up” box would appear when the physician ordered a red blood cell transfusion. The message encouraged a transfusion protocol for using a single unit of red blood cells and rechecking the patient’s hemoglobin and hematocrit before transfusing another red blood cell unit. This program decreased the red blood cell utilization by 27.2% across the three hospitals within the Johns Hopkins Hospital System. Both the Stanford and Johns Hopkins studies proved that there are several methods that hospitals can employ to encourage physicians to conform to a more strict blood utilization process. Like the results seen in our study, these data further demonstrate that Blood utilization programs are effective in reducing blood product utilization.

In order for the blood utilization guidelines to work effectively, it was essential to educate and enforce upon FMH physicians and ordering nursing staff to follow the new set of blood utilization guidelines. Without this step, the entire project would not have been as successful. Also, monthly reports are evaluated by the blood bank supervisor to review all blood production transfusions and the laboratory test triggers. It is up to the discretion of the Blood Bank supervisor to submit any patients whose results and transfusion history do not follow the current blood utilization guidelines to the blood utilization committee. Quarterly, the pathologists on the blood utilization committee evaluate the reviewed patients to determine if the transfusion was necessary. The committee invites the physician who ordered the transfusion to participate in
the review. From the discussions during the review process, the committee determines what steps need to be taken to avoid unnecessary transfusions in the future.

**Future Directions**: Recently, FMH implemented a new instrument for processing complete blood counts, the Sysmex XN-3000 (Kobe, Japan). In addition to the continued use of the blood utilization guidelines, this machine offers two new tests that could reduce red blood cell and platelet transfusions. The two tests are the immature platelet fraction (IPF) and reticulocyte hemoglobin equivalent (RET-He). IPF is a measurement aimed to evaluate thrombopoiesis in patients. As the bone marrow produces platelets, the IPF level in a patient increases as well. Patients with a low platelet count (<50 x 10^9/L) will automatically have an IPF result generated. This laboratory test does not replace the platelet count as the deciding factor in assessing the need for a platelet transfusion, but can be helpful in determining if the patient has a production or destruction problem. Sysmex sponsored a study for predicting thrombopoietic recovery in patients who received autologous stem cell transplantation. It is common for a patient who received a stem cell transplant to also receive a prophylactic platelet transfusion regardless of the patient’s platelet count. The study determined that a cutoff value of 5.3% IPF would predict thrombopoietic recovery within 2 days of a stem cell transplant. By allowing a patient’s own body to recover and produce platelets, patients are less likely to require a platelet transfusion and be exposed to the possible side effects associated with a transfusion.

RET-He, which is a test that measures the hemoglobin content in circulating reticulocytes, is a useful laboratory tool to monitor and diagnose iron deficiency anemia. A RET-He result would allow a physician to first determine if iron deficiency is the cause of their patient’s anemia and have the opportunity to prescribe iron vitamin supplements before ordering
a red blood cell transfusion. RET-He testing is performed with every reticulocyte count ordered in FMH. A study in the Intensive Care Unit of Hospital Sant Joan de Deu in Spain used RET-He to evaluate patients functioning with iron deficiency and the requirement for blood transfusions while admitted to the ICU. The findings of this study confirmed that a lower RET-He value required higher transfusions requirements.\textsuperscript{11} Consequently, the IPF and RET-He tests will offer physicians more tools to help diagnose and determine the right treatment plans for their patients and have the potential to enhance the outcomes of the current blood utilization guidelines. To evaluate the effectiveness of the IPF and RET-He tests in the future, the blood utilization committee will compare transfusions and the ordering of these two tests.
REFERENCES:


<table>
<thead>
<tr>
<th>2008</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Red Blood Cells:</strong></td>
<td><strong>Red Blood Cells:</strong></td>
</tr>
<tr>
<td>• Regardless of the patient’s hemoglobin value a normovolemic patient with symptomatic anemia</td>
<td>• Hematocrit ≤ 21% or hemoglobin ≤ 7 g/dL in a patient with no known cardiorespiratory disease</td>
</tr>
<tr>
<td>• Patient with acute blood loss of &gt;15% of estimated blood volume</td>
<td>• Hematocrit ≤ 25% or hemoglobin ≤ 8.5 g/dL in a patient with cardiac, cerebral or other major organ ischemia or hypoproliferative anemia</td>
</tr>
<tr>
<td>• Patient with acute blood loss with evidence of adequate oxygen delivery</td>
<td>• Rapid blood loss with &gt; 20% of estimated blood volume (&gt;1000 mL) not responding to appropriate volume resuscitation, or with ongoing blood loss.</td>
</tr>
<tr>
<td>• Preoperative hemoglobin 8 g/dL and operative procedure associated with major blood loss</td>
<td></td>
</tr>
<tr>
<td>• Hemoglobin &lt;8 g/dL in a patient on a chronic transfusion regimen</td>
<td></td>
</tr>
<tr>
<td><strong>Platelets: no recommended guidelines</strong></td>
<td><strong>Platelet</strong></td>
</tr>
<tr>
<td>• Platelet count ≤ 10,000/uL prophylactically in a patient with failure of platelet production</td>
<td>• Platelet count ≤ 10,000/uL in a bleeding</td>
</tr>
<tr>
<td>• Platelet count ≤ 20,000/uL and signs of hemorrhagic diathesis (petechiae, mucosal bleeding)</td>
<td>• Platelet count ≤ 20,000/uL and signs of hemorrhagic diathesis (petechiae, mucosal bleeding)</td>
</tr>
<tr>
<td>• Platelet count ≤ 50,000/uL in a bleeding</td>
<td>• Platelet count ≤ 50,000/uL in a bleeding</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Plasma: no recommended guidelines</strong></td>
<td><strong>Plasma:</strong></td>
</tr>
<tr>
<td></td>
<td>• Active hemorrhage</td>
</tr>
<tr>
<td></td>
<td>• Platelet dysfunction as documented by platelet function test result(s) or medication known to cause platelet dysfunction</td>
</tr>
<tr>
<td></td>
<td>• Active bleeding, or a patient undergoing an invasive procedure with an INR &gt;1.6 or APTT &gt;40 seconds</td>
</tr>
<tr>
<td></td>
<td>• Plasma exchange for TTP or hemolytic uremic syndrome (HUS)</td>
</tr>
<tr>
<td></td>
<td>• Emergency reversal of warfarin</td>
</tr>
<tr>
<td><strong>Cryoprecipitate: no recommended guidelines</strong></td>
<td><strong>Cryoprecipitate:</strong></td>
</tr>
<tr>
<td></td>
<td>• Fibrinogen ≤ 100 mg/dL</td>
</tr>
<tr>
<td></td>
<td>• Renal failure with an abnormal closure time (platelet function test) and one of the following: active hemorrhage, surgery, or invasive procedure within 24 hours</td>
</tr>
<tr>
<td></td>
<td>• Von Wilebrand’s disease if DDAVP or Humate P (or comparable factor concentrate) is not available</td>
</tr>
</tbody>
</table>
Table 2 – Current AABB Platelet transfusion guidelines\textsuperscript{7}

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Platelet count threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>10,000 uL</td>
</tr>
<tr>
<td>Stable patients</td>
<td>5,000 uL</td>
</tr>
<tr>
<td>Patients with fever or recent hemorrhage</td>
<td>10,000 uL</td>
</tr>
<tr>
<td>Patients with coagulopathy on heparin, or with anatomic lesion likely to bleed</td>
<td>20,000 uL</td>
</tr>
</tbody>
</table>

Figure 1 – Total number both irradiated and non-irradiated leukoreduced red blood cell transfusions at FMH from 2010 to 2017.

Figure 2 - Total number fresh frozen plasmapheresis transfusions at FMH from 2010 to 2017.
Figure 3 - Total number cryoprecipitate transfusions that have taken place at FMH from 2010 to 2017.

Figure 4 - Total number both irradiated and non-irradiated platelet apheresis transfusions at FMH from 2010 to 2017.
Figure 5 – Total number of recorded transfusion reactions that occurred at FMH from 2010 to 2017.